(d) Appointment of Director

Effective as of June 4, 2019, the Board of Directors (the “Board”) of Revance Therapeutics, Inc. (the “Company”) elected Jill Beraud to serve as a member of the Board for the term expiring at the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) and until her successor is duly elected and qualified, or until her earlier death, resignation or removal. Ms. Beraud’s appointment was recommended to the Board by its Nominating and Corporate Governance Committee.

In accordance with the Company’s Non-Employee Director Compensation Policy (the “Policy”), Ms. Beraud is entitled to receive a $40,000 annual retainer for service as a Board member. Effective as of June 4, 2019, Ms. Beraud was granted an option to purchase 18,000 shares of common stock under the Company’s 2014 Equity Incentive Plan with an exercise price equal to $10.99 and 9,000 shares of restricted common stock. The option and stock award will vest on the one year anniversary of the date of grant, subject to Ms. Beraud’s continued service as a director through the vesting date.

The Company also entered into the Company’s standard form of indemnification agreement with Ms. Beraud. The indemnification agreement provides, among other things, that the Company will indemnify Ms. Beraud for certain expenses which she may be required to pay in connection with certain claims to which she may be made a party by reason of her position as a director of the Company, and otherwise to the fullest extent permitted under Delaware law and the Company’s Amended and Restated Bylaws. The form of indemnification agreement was previously filed as Exhibit 10.8 to the Company’s Registration Statement on Form S-1 (No. 333-193154), as amended, as filed on January 27, 2014, and is incorporated herein by reference.

There are no arrangements or understandings between Ms. Beraud and any other persons to which she was elected as a director of the Company. There are no family relationships between Ms. Beraud and any director, executive officer, or any person nominated or chosen by the Company to become a director or executive officer. There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission) between Ms. Beraud and the Company.

A copy of the Company’s press release announcing the appointment of Ms. Beraud is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Revance Therapeutics, Inc. Exhibit
EX-99.1 2 rvnc20198-kjune6exhibit991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Revance Adds Iconic Brand Builder Jill Beraud to Board of Directors- Beraud will also chair newly-formed Brand Strategy Committee – NEWARK,…
To view the full exhibit click here

About Revance Therapeutics, Inc. (NASDAQ:RVNC)

Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.